清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication

作者
Javier Cid Ruzafa,Sinna Pilgaard Ulrichsen,Dimitri Bennett,Véra Ehrenstein
出处
期刊:Drugs - real world outcomes [Adis, Springer Healthcare]
卷期号:6 (3): 133-140 被引量:3
标识
DOI:10.1007/s40801-019-0160-6
摘要

INTRODUCTION: A Direct Healthcare Professional Communication (DHPC) sent in Denmark on 11 August 2011 provided information on new pioglitazone labelling and guidance on monitoring treatment effectiveness. We describe pioglitazone use in Denmark after the DHPC, estimate the incidence of heart failure (HF), quantify pioglitazone cessation following a diagnosis of bladder cancer (BC) or uninvestigated macroscopic haematuria, and describe glycated haemoglobin (HbA1c) values. METHODS: This was a cohort study. From Danish population-based registries, cohorts of type 2 diabetes mellitus incident or prevalent users of pioglitazone or insulin in 2011-2015 were created. Patient characteristics, treatment patterns, laboratory results (available for a regional subset of the population), and incidence rates of HF and BC were estimated. RESULTS: There were 80 pioglitazone and 17,699 insulin incident users, 140 pioglitazone and 13,183 insulin prevalent users. There were no new BC cases among incident pioglitazone users, and < 5 new BC cases among prevalent pioglitazone users. Pioglitazone was rarely the first-line treatment. History of haematuria was documented in < 5 incident and 11 prevalent pioglitazone users. During follow-up, there were < 5 HF cases among 77 incident pioglitazone users and < 5 among 133 prevalent pioglitazone users without a history of HF. Median HbA1c at index date was 7.8% and 8.8% in incident pioglitazone and insulin cohorts, and 7.5% and 7.6% in prevalent pioglitazone and insulin cohorts, respectively. During follow-up of up to 4.4 years, 28.8% incident and 20.7% prevalent pioglitazone users discontinued pioglitazone. CONCLUSIONS: Numbers of pioglitazone users in Denmark were low and decreased over time. Risks of BC or HF were low and risk estimates imprecise.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XiaonanTang完成签到 ,获得积分10
2秒前
Karl完成签到,获得积分10
8秒前
zzz完成签到,获得积分10
13秒前
QQQQQQ完成签到 ,获得积分10
23秒前
谦让的沛芹完成签到,获得积分10
29秒前
rockyshi完成签到 ,获得积分10
31秒前
yx完成签到 ,获得积分10
32秒前
称心的高丽完成签到 ,获得积分10
35秒前
怕黑的夏之完成签到,获得积分10
51秒前
n01W97的应助被科研通管家采纳,获得20
57秒前
57秒前
领导范儿的应助被科研通管家采纳,获得10
57秒前
57秒前
星辰大海的应助被科研通管家采纳,获得10
57秒前
Maestro_S的应助被科研通管家采纳,获得10
57秒前
共享精神的应助被科研通管家采纳,获得10
58秒前
脑洞疼的应助被小小采纳,获得10
1分钟前
赘婿的应助被小小采纳,获得10
1分钟前
蔡勇强完成签到 ,获得积分10
1分钟前
王馨完成签到 ,获得积分10
1分钟前
Elsevier大王的应助被小小采纳,获得30
1分钟前
脑洞疼的应助被小小采纳,获得10
1分钟前
自然的妙梦完成签到,获得积分10
1分钟前
粗暴的画板完成签到,获得积分10
1分钟前
cdercder的应助被小小采纳,获得10
1分钟前
领导范儿的应助被依然灬聆听采纳,获得10
1分钟前
科目三的应助被小小采纳,获得10
1分钟前
诚心金渐基完成签到 ,获得积分10
1分钟前
独特的高山完成签到 ,获得积分10
1分钟前
田様的应助被小小采纳,获得10
1分钟前
wcl完成签到,获得积分10
1分钟前
孙文杰完成签到 ,获得积分0
1分钟前
万能图书馆的应助被小小采纳,获得10
2分钟前
可爱沛蓝完成签到 ,获得积分10
2分钟前
隐形曼青的应助被小小采纳,获得10
2分钟前
成就的翠芙完成签到,获得积分10
2分钟前
睡不醒完成签到 ,获得积分10
2分钟前
瘦瘦的巧凡完成签到,获得积分10
2分钟前
fantasy的应助被小小采纳,获得10
2分钟前
小白完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834496
捐赠科研通 7783045
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558912
邀请新用户注册赠送积分活动 2481326